AMRN Q4 2025 Earnings — Amarin Corporation plc Revenue & Financial Results | Market Cap Arena

AMRNAmarin Corporation plc

$310M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M-68.8% YoY

Gross Profit

$23M119.2% margin

Operating Income

$20M105.4% margin

Net Income

-$1M-6.3% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

-60.9%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

-$12M

Balance Sheet

Total Assets

$671M

Total Liabilities

$211M

Stockholders' Equity

$459M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$62M	-68.8%
Gross Profit	$23M	-$10M	+342.2%
Operating Income	$20M	-$53M	+139.0%
Net Income	-$1M	-$49M	+97.5%

Revenue Segments

Product

$47M95%

Licensing And Royalty

$3M5%

Geographic Segments

UNITED STATES

$41M95%

Europe

$2M5%